Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

BACKGROUND: Response rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy. METHODS: We conducted a single-arm, phase II study of patients with triple negative (TN...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Shah, Ami N, Flaum, Lisa, Helenowski, Irene, Santa-Maria, Cesar A, Jain, Sarika, Rademaker, Alfred, Nelson, Valerie, Tsarwhas, Dean, Cristofanilli, Massimo, Gradishar, William
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057426/
https://ncbi.nlm.nih.gov/pubmed/32060053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000173
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares